FindTrial
Sign In

Treatment Phase

2 trials

Sponsors

Celgene Corporation, Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb company

Conditions

Myeloproliferative Neoplasm-associated Myelofibrosis with concomitant JAK2 inhibitor therapy requiring red blood cell transfusions. MyelofibrosisPrior participation on a clinical trial of luspatercept (ACE-536) in protocols eligible for participation in this study ACE-536-LTFU-001 with the following medical conditions: - Myelodysplastic Syndrome (MDS) - Beta (ß)-thalassemia (THAL) - Myelofibrosis (MF) In Lebanon, only patients with beta (ß)-thalassemia (THAL) have participated in previuos clinical trial of luspatercept (ACE-536). Thalassemia

Phase 3

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
RecruitingLBCTR2023075332
Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb companyMyeloproliferative Neoplasm-associated Myelofibrosis with concomitant JAK2 inhibitor therapy requiring red blood cell transfusions. Myelofibrosis
Start: 2021-02-25Target: 309Updated: 2026-02-02
A Phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536) clinical trials
RecruitingLBCTR2019100218
Celgene CorporationPrior participation on a clinical trial of luspatercept (ACE-536) in protocols eligible for participation in this study ACE-536-LTFU-001 with the following medical conditions: - Myelodysplastic Syndrome (MDS) - Beta (ß)-thalassemia (THAL) - Myelofibrosis (MF) In Lebanon, only patients with beta (ß)-thalassemia (THAL) have participated in previuos clinical trial of luspatercept (ACE-536). Thalassemia
Start: 2020-02-19Target: 742Updated: 2026-02-02